Treatment options in the management of actinic keratosis

Cutis

Volumn 74, Issue 6 SUPPL., 2004, Pages 9-17

  Jorizzo, Joseph L ^a,j   Carney, Patrick S ^b,c,d,k   Ko, William T ^e,k   Robins, Perry ^f,k   Weinkle, Susan H ^g,l   Werschler, Wm Philip ^h,i,m  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Advancements in Dermatology   (United States)

^d SkinSpeaks Spa MD   (United States)

^e Arizona Skin and Laser Ther Inst   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g Spokane Dermatology Clinic ^*

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ Spokane Dermatology Clinic   (United States)

^j 3M COMPANY   (United States)

^k Dermik Laboratories   (United States)

^l Galderma Laboratories   (United States)

^m Valeant Pharmaceuticals International   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYACID; ADAPALENE; COLCHICINE; CORTICOSTEROID; DICLOFENAC; FLUOROURACIL; GLYCOLIC ACID; IMIQUIMOD; ISOTRETINOIN; PYRUVIC ACID; RETINOIC ACID; RETINOID;

ACTINIC KERATOSIS; ARTICLE; BLISTER; BURNING SENSATION; CLINICAL FEATURE; CLINICAL OBSERVATION; CLINICAL TRIAL; CREAM; CRYOTHERAPY; CURETTAGE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG USE; DRY SKIN; ECONOMIC ASPECT; EDEMA; ERYTHEMA; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALING; HEALTH INSURANCE; HUMAN; INFECTION; IRRADIATION; LIFESTYLE; LOW LEVEL LASER THERAPY; OUTCOMES RESEARCH; PATIENT; PHOTODYNAMIC THERAPY; PHYSICIAN; PIGMENT DISORDER; PRESCRIPTION; PRURITUS; RISK ASSESSMENT; SCAR FORMATION; SIDE EFFECT; SKIN IRRITATION; SKIN PIGMENTATION; SKIN ULCER; SURGICAL TECHNIQUE;

COMBINED MODALITY THERAPY; COSMETIC TECHNIQUES; DERMATOLOGIC AGENTS; HUMANS; KERATOSIS; PHOTOSENSITIVITY DISORDERS; PHYSICAL THERAPY MODALITIES;

EID: 12344326134     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Gupta AK, Cooper EA, Feldman SR, et al. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey. Cutis. 2002;70(suppl 2):8-13.
2. Feldman SR, Fleischer AB, Williford PM, et al. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol. 1999;40:43-47.
3. American Academy of Dermatology. ActinicKeratosisNet Treatment Options. Available at: http://www.skincarephysicians.com /actinickeratosesnet/treatment. htm. Accessed August 10, 2004.
4. Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol. 1982;7:631-632.
5. Chiarello SE. Full-face cryo- (liquid nitrogen) peel. J Dermatol Surg Oncol. 1992;18:329-332.
6. Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg. 2000;26:728-732.
7. Quaedvlieg PJ, Ostertag JU, Krekels GA, et al. Delayed wound healing after three different treatments for widespread actinic dermatosis on the scalp. Dermatol Surg. 2003;29:1052-1056.
8. Freeman RG, Knox JM, Heaton CL. The treatment of skin cancer. a statistical study of 1,341 skin tumors comparing results obtained with irradiation, surgery, and curettage followed by electrodesiccation. Cancer. 1964;17:535-538.
9. Harmon CB. Dermabrasion. Available at: http://www.emedicine.com/derm/ topic744.htm. Accessed August 18, 2004.
10. Winton GB, Salasche SJ. Dermabrasion of the scalp as a treatment for actinic damage. J Am Acad Dermatol. 1986;14:661-668.
11. Coleman WP 3rd, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg. 1996;22:17-21.
12. Iyer S, Friedl A, Bowes L, et al. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med. 2004;34:114-119.
13. 2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg. 1999;25:729-732.
14. Thomas WO, Hendrix D, Rayburn SD, et al. Laser resurfacing complication. South Med J. 1999;92:999-1001.
15. Price-Chek PC. Wolters Kluwer Health Inc. Available at: www.medispan.com. Accessed October 1, 2004.
16. Jorizzo JL, Carney PS, Ko WT, et al. Matching patients with therapy. Cutis. 2004;74(suppl 6):5-8.
17. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990-1000.
18. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther. 2001;23:901-907.
19. Levy S, Furst K, Chern W. A pharmacokinetic evaluation of the 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther. 2001;23:908-920.
20. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002;70:30-36.
21. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131:175-181.
22. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335-339.
23. Labandeira J, Pereiro M Jr, Valdes F, et al. Intermittent topical 5-fluorouracial is effective without significant irritation in the treatment of actinic keratoses but prolongs treatment duration. Dermatol Surg. 2004;30:517-520.
24. Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol. 1991;25:665-667.
25. Robins P. Pulse therapy with 5-FU in eradicating actinic keratoses with less than recommended dosage. J Drugs Dermatol. 2002;1:25-30.
26. Breza T, Taylor R, Eaglstein WH. Noninflammatory destruction of actinic keratoses by fluorouracil. Arch Dermatol. 1976;122:1256-1258.
27. Witheiler DD, Lawrence N, Cox SE, et al. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997;23:191-196.
28. Ghersetich I, Brazzini B, Peris K, et al. Pyruvic acid peels for the treatment of photoaging. Dermatol Surg. 2004;30:32-36.
29. Marrero GM, Katz BE. The new fluor-hydroxy pulse peel. a combination of 5-fluorouracil and glycolic acid. Dermatol Surg. 1998;24:973-978.
30. Aldara [package insert]. St. Paul, Minn: 3M Pharmaceuticals; 2004.
31. Tyring S. Imiquimod applied topically: a novel immune response modifier. Skin Therapy Lett. 2001;6(6):1-4.
32. Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol. 2001;144:1050-1053.
33. Chen K, Yap LM, Marks R, et al. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol. 2003;44:250-255.
34. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol. 2002;47:571-577.
35. Persaud AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol. 2002;47:553-556.
36. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III randomized, double-blind, parallel group, vehicle-controlled) trials. J Am Acad Dermatol. 2004;50:714-721.
37. Harrison LI, Skinner SL, Marbury TC, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol. 2004;296:6-11.
38. Carney PS. Understanding new options for AKs: from the lab to the clinic. Pract Dermatol. 2004;1:8-11.
39. Peters CD, Foster RH. Diclofenac/hyaluronic acid. Drugs Aging. 1999;14:313-319.
40. Rivers JK. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses. Skin Therapy Lett. 2004;9(1):1-3.
41. Solaraze Gel [package insert]. Malvern, Penn: Bioglan Pharmaceuticals; 2003.
42. Wolf JE Jr, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709-713.
43. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146:94-100.
44. Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004;3:401-407.
45. Alirezai M, Dupuy P, Amblard P, et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J Am Acad Dermatol. 1994;30:447-451.
46. Misiewicz J, Sendagorta E, Golebiowska A, et al. Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol. 1991;24:448-451.
47. Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol. 2003;49:83-90.
48. Suthamjariya K, Taylor CR. Photodynamic therapy for the dermatologist. Available at: http://www.emedicine.com /derm/topic636.htm. Accessed August 19, 2004.
49. Szeimies RM, Karrer S, Sauerwald A, et al. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology. 1996;192:246-251.
50. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid, a pilot dose-ranging study. Arch Dermatol. 1997;133:727-732.
51. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol. 2001;45:96-104.
52. Piacquadio DJ, Chen DM, Farber HP, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140:41-46.
53. Fowler JF Jr, Zax RH. Aminolevulinic acid hydrochloride with photodynamic therapy: efficacy outcomes and recurrence 4 years after treatment. Cutis. 2002;69(suppl 6):2-7.
54. Kurwa HA, Yong-Gee SA, Seed PT, et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol. 1999;41:414-418.
55. Smith S, Piacquadio D, Morhenn V, et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol. 2003;2:629-635.
56. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective randomized study. J Am Acad Dermatol. 2002;47:258-262.
57. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48:227-232.
58. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatol Treat. 2003;14:99-106.
59. Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double-blind controlled study. Br J Dermatol. 1987;116:549-552.
60. Robinson TA, Kligman AM. Treatment of solar keratoses of the extremities with retinoic acid and 5-fluorouracil. Br J Dermatol. 1975;92:703-706.
61. Goncalves JC. Treatment of solar keratoses with a 5-fluorouracil and salicylic acid varnish. Br J Dermatol. 1975;92:85-88.
62. Griffin TD, Van Scott EJ. Use of pyruvic acid in the treatment of actinic keratoses: a clinical histopathologic study. Cutis. 1991;47:325-329.
63. Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery. Arch Dermatol. 2004;140:813-816.
64. Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluation masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24:738-743.
65. Grimaitre M, Etienne A, Fathi M, et al. Topical colchicine therapy for actinic keratoses. Dermatology. 2000;200:346-348.
66. Akar A, Bulent Tastan H, Erbil H, et al. Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses. J Dermatol Treat. 2001;12:199-203.